As expected, the pCR rates varied by subtype with a low rate of 12% in HR-positive, HER2-negative, higher rates of 36 and 38% in HR-positive, HER2-positive and triple-negative and the highest rate of 55% in HR-negative, HER2-positive cancers. This evidence concerns the gene ERBB2 and cancer.